Drug Trial Radar · NCT00723983
Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period
Last checked: Nov 19, 2026Latest source record: Feb 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
23
Actual
Start
Nov 2008
Primary completion
Sep 2009
Study completion Sep 2009
Sponsor
- Lead sponsor
- NuPathe Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 29, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the pharmacokinetics of NP101 with a currently approved oral formulation of Imitrex® (50 mg) in migraine subjects both during an acute migraine attack and during a non-migraine period.
Conditions
- Migraine Disorders
Interventions
Sumatriptan succinateDrug
Sumatriptan succinate 50 mg taken orally
NP101 Study PatchDrug
NP101 study patch 4 hour application
Primary outcomes
What the sponsor says the trial is designed to measure.
- Compare the pharmacokinetics of NP101 with a currently approved formulation of Imitrex in migraine subjects during an acute migraine attack and during a non-migraine period.Time frame: PK samples at pre and 0.25, 0.5, 1, 1.25, 1.5, 1.75, 2, 3, 4, 6, 8, 10, 12 and 24 hours post each dose/period for Periods 1, 2, 3, and 4 [24 hour PK will not be done for Periods 5 and 6]
Locations
1 site in 1 country. Site status is shown where the registry gives one.
MD Clinic
Hallandale, Florida
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.